ASCO 2024 HER2-Mutated NSCLC

Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP, discusses updated data from the phase 1a/1b trial of zongertinib in patients with HER2 aberration-positive solid tumors. In this video, she reports data from phase 1b, the ongoing dose expansion phase, which includes patients with HER2 mutation–positive NSCLC and focuses on nursing considerations for managing adverse events.

Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP, discusses the trial design of Beamion LUNG-2, a randomized phase 3 trial of zongertinib versus standard of care in patients with locally advanced or metastatic NSCLC harboring HER2 tyrosine kinase domain (TKD) mutations. She discusses the role of nurses in clinical trials, including providing essential monitoring and support to patients during their trial participation.

Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP, discusses results from an exposure-efficacy and exposure-safety analysis of trastuzumab deruxtecan in patients with HER2-mutated NSCLC. In her recap, she highlights the importance of education around dose adjustments to manage patient expectations.

Final results from the randomized phase 2 trial of trastuzumab deruxtecan in patients with HER2-mutant NSCLC were reported at ASCO 2024 and summarized in this video by Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP. She recaps the efficacy and safety data while highlighting the importance of nurses in assessing and managing adverse events associated with these medications.